Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 2 (2005), Issue 4 (April)

1. The tau gene haplotype h1 confers a susceptibility to Parkinson's disease.
   Eur Neurol, 53(1): 15-21. [Abstract] [Full-text]
2. Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease.
   Int J Neurosci, 115(4): 479-93. [Abstract] [Full-text]
3. Comparison of 2-dimensional magnetic resonance imaging and 3-planar reconstruction methods for targeting the subthalamic nucleus in Parkinson disease.
   Surg Neurol, 63(4): 357-62; discussion 362-3. [Abstract] [Full-text]
4. High-frequency stimulation in Parkinson's disease: more or less?
   Trends Neurosci, 28(4): 209-16. [Abstract] [Full-text]
5. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia.
   Clin Endocrinol (Oxf), 62(4): 428-33. [Abstract] [Full-text]
6. Treatment of behavioural symptoms and dementia in Parkinson's disease.
   Fundam Clin Pharmacol, 19(2): 133-46. [Abstract] [Full-text]
7. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
   Hum Psychopharmacol, 20(3): 203-5. [Abstract] [Full-text]
8. Influence of high motor unit synchronization levels on non-linear and spectral variables of the surface EMG.
   J Neurosci Methods, 143(2): 133-9. [Abstract] [Full-text]
9. Levodopa-induced modulation of subthalamic beta oscillations during self-paced movements in patients with Parkinson's disease.
   Eur J Neurosci, 21(5): 1403-12. [Abstract] [Full-text]
10. Stimulation through electrodes implanted near the subthalamic nucleus activates projections to motor areas of cerebral cortex in patients with Parkinson's disease.
    Eur J Neurosci, 21(5): 1394-402. [Abstract] [Full-text]
11. Scientific evaluation of community-based Parkinson's disease nurse specialists on patient outcomes and health care costs.
    J Eval Clin Pract, 11(2): 97-110. [Abstract] [Full-text]
12. Memory for time intervals is impaired in left hemi-Parkinson patients.
    Neuropsychologia, 43(8): 1163-7. [Abstract] [Full-text]
13. Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations.
    J Neurochem, 93(2): 422-31. [Abstract] [Full-text]
14. Facial expression decoding in early Parkinson's disease.
    Brain Res Cogn Brain Res, 23(2): 327-40. [Abstract] [Full-text]
15. Deep-brain stimulation in the subthalamic nuclei improves balance performance in patients with Parkinson's disease, when tested without anti-parkinsonian medication.
    Acta Neurol Scand, 111(5): 301-8. [Abstract] [Full-text]
16. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
    Arch Neurol, 62(4): 601-5. [Abstract] [Full-text]
17. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease.
    Arch Neurol, 62(4): 554-60. [Abstract] [Full-text]
18. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases.
    Acta Derm Venereol, 85(2): 136-9. [Abstract] [Full-text]
19. Visuo-spatial processing in Parkinson's disease: evidence for diminished visuo-spatial sketch pad and central executive resources.
    Parkinsonism Relat Disord, 11(3): 181-6. [Abstract] [Full-text]
20. Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study.
    Parkinsonism Relat Disord, 11(3): 173-80. [Abstract] [Full-text]
21. Effect of subthalamic nucleus stimulation patterns on motor performance in Parkinson's disease.
    Parkinsonism Relat Disord, 11(3): 167-71. [Abstract] [Full-text]
22. Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study.
    Parkinsonism Relat Disord, 11(3): 157-65. [Abstract] [Full-text]
23. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Parkinsonism Relat Disord, 11(3): 151-5. [Abstract] [Full-text]
24. Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort.
    Parkinsonism Relat Disord, 11(3): 139-45. [Abstract] [Full-text]
25. Validating the Berg Balance Scale for patients with Parkinson's disease: a key to rehabilitation evaluation.
    Arch Phys Med Rehabil, 86(4): 789-92. [Abstract] [Full-text]
26. Efficacy of a physical therapy program in patients with Parkinson's disease: a randomized controlled trial.
    Arch Phys Med Rehabil, 86(4): 626-32. [Abstract] [Full-text]
27. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
    Mov Disord, 20(4): 395-402. [Abstract] [Full-text]
28. [18F]FDOPA PET and clinical features in parkinsonism due to manganism.
    Mov Disord, 20(4): 492-6. [Abstract] [Full-text]
29. Differential pattern of hand-tapping compromise in vascular versus idiopathic parkinsonism: a study based on computerized movement analysis.
    Mov Disord, 20(4): 504-8. [Abstract] [Full-text]
30. Swallowing abnormalities and dyskinesia in Parkinson's disease.
    Mov Disord, 20(4): 457-62. [Abstract] [Full-text]
31. Olfaction testing in patients with tremor-dominant Parkinson's disease: is this a distinct condition?
    Mov Disord, 20(4): 471-5. [Abstract] [Full-text]
32. Force control and disease severity in Parkinson's disease.
    Mov Disord, 20(4): 441-50. [Abstract] [Full-text]
33. Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation.
    Mov Disord, 20(4): 416-23. [Abstract] [Full-text]
34. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
    Mov Disord, 20(4): 403-9. [Abstract] [Full-text]
35. Does severity of Parkinson's disease vary according to season?
    Mov Disord, 20(4): 476-9. [Abstract] [Full-text]
36. Pallidotomy effect on the cortical excitability in patients with severe Parkinson's disease.
    Mov Disord, 20(4): 463-70. [Abstract] [Full-text]
37. Novel parkin mutations detected in patients with early-onset Parkinson's disease.
    Mov Disord, 20(4): 424-31. [Abstract] [Full-text]
38. Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes.
    Mov Disord, 20(4): 410-5. [Abstract] [Full-text]
39. Parkinson's disease risk factors: genetic, environmental, or both?
    Neurol Res, 27(2): 206-8. [Abstract] [Full-text]
40. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis.
    Hum Mol Genet, 14(9): 1231-41. [Abstract] [Full-text]
41. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life.
    Clin Auton Res, 15(2): 76-82. [Abstract] [Full-text]
42. Neurogenetics II: complex disorders.
    J Neurol Neurosurg Psychiatry, 76(5): 623-31. [Abstract] [Full-text]
43. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Mov Disord, 20: S3-10. [Abstract] [Full-text]
44. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.
    Mov Disord, 20: S11-6. [Abstract] [Full-text]
45. Pathophysiology of motor fluctuations in Parkinson's disease.
    Mov Disord, 20: S17-22. [Abstract] [Full-text]
46. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
    Mov Disord, 20: S30-7. [Abstract] [Full-text]
47. Nonmotor complications in Parkinson's disease.
    Mov Disord, 20: S23-9. [Abstract] [Full-text]
48. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.
    Mol Pharmacol, 67(5): 1544-55. [Abstract] [Full-text]
49. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Neurobiol Dis, 19(1): 96-107. [Abstract] [Full-text]
50. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions.
    Neuroscience, 132(3): 767-76. [Abstract] [Full-text]
51. Evidence of a breakdown of corticostriatal connections in Parkinson's disease.
    Neuroscience, 132(3): 741-54. [Abstract] [Full-text]
52. Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in Parkinson's disease.
    Behav Brain Res, 160(1): 188-94. [Abstract] [Full-text]
53. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
    Behav Brain Res, 160(1): 148-60. [Abstract] [Full-text]
54. Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders.
    Acta Neuropathol (Berl), 109(3): 256-62. [Abstract] [Full-text]
55. Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease.
    Neurosci Lett, 379(3): 195-8. [Abstract] [Full-text]
56. Phosphorylated IkappaBalpha is a component of Lewy body of Parkinson's disease.
    Biochem Biophys Res Commun, 331(1): 309-17. [Abstract] [Full-text]
57. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    J Neurosci Methods, 144(1): 35-45. [Abstract] [Full-text]
58. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Brain Res Brain Res Rev, 48(2): 379-87. [Abstract] [Full-text]
59. Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson's disease in Japan.
    J Neurol Sci, 232(1): 91-4. [Abstract] [Full-text]
60. Role of peroxidases in Parkinson disease: a hypothesis.
    Free Radic Biol Med, 38(10): 1296-310. [Abstract] [Full-text]
61. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.
    Nat Neurosci, 8(5): 657-63. [Abstract] [Full-text]
62. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons.
    J Neurochem, 93(4): 974-83. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.